For research use only. Not for therapeutic Use.
Dostarlimab（Cat No.:I042245）is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. By blocking PD-1, Dostarlimab enhances the immune system’s ability to recognize and attack cancer cells. It has shown promise in treating various cancers, particularly mismatch repair-deficient solid tumors, including endometrial cancer. Dostarlimab is being investigated in clinical trials for its efficacy in combination with other therapies. Its immune checkpoint inhibition approach is part of the growing field of immunotherapy aimed at improving cancer treatment outcomes by overcoming tumor-induced immune suppression.
| Catalog Number | I042245 |
| CAS Number | 2022215-59-2 |
| Purity | ≥95% |
